巩固 胡占升

    [摘要] 目的 研究利奈唑胺联合盐酸氨溴索治疗呼吸机相关性肺炎(VAP)患者的效果及对血清胰石蛋白(PSP)、可溶性髓样细胞触发受体-1(sTREM-1)水平的影响。 方法 选取锦州市中心医院2016年10月～2017年10月收治的90例VAP患者，按照随机数字表法分为观察组和对照组，每组45例，其中对照组采用利奈唑胺治疗，观察组采用利奈唑胺和盐酸氨溴索治疗，两组均治疗7 d。比较两组患者临床疗效、临床指标，以及血清炎性因子、PSP和sTREM-1水平。 结果 治疗后，观察组总有效率、病原菌清除率、吸痰次数、机械通气时间、ICU住院时间以及血清炎性因子水平显著优于对照组(P < 0.05)。治疗后两组患者的血清PSP、sTREM-1水平较治疗前显著降低，其中观察组血清PSP、sTREM-1水平显著低于对照组(P < 0.05)。 结论 利奈唑胺联合盐酸氨溴索治疗VAP效果显著，可有效提高抗菌效力，降低血清PSP、sTREM-1水平，减轻炎性反应，改善预后。

    [关键词] 呼吸机相关性肺炎；PSP；sTREM-1

    [中图分类号] R563 [文献标识码] A [文章编号] 1673-7210(2018)09(a)-0140-04

    [Abstract] Objective To analyze the effect of Linezolid combined with Ambroxol Hydrochloride on Ventilator associated pneumonia (VAP) and its effect on serum PSP/sTREM-1 levels. Methods A total of 90 patients with VAP admitted in Jinzhou Central Hospital from October 2016 to October 2017 were collected and they were divided into observation group and control group according to the random number table method， with 45 cases in each group. The control group was treated with Linezolid， while the observation group was treated with Linezolid and Ambroxol Hydrochloride. Both groups were treated for 7 days. The clinical efficacy ......